Two isoforms, alpha and beta, make up the multifunctional serine/threonine kinase known as glycogen synthase kinase-3 (GSK-3). It controls the receptor tyrosine kinase, cytokine, and Wnt signaling pathways negatively and is highly conserved. Inhibiting GSK-3 through the stimulation of these pathways affects a variety of downstream effectors, such as transcription factors, nutrient sensors, glycogen synthesis, mitochondrial function, circadian rhythm, and cell fate. In response to T-cell receptor activation, GSK-3 also controls alternative splicing, and current phosphoproteomic studies have shown that numerous splicing regulators and splicing factors are phosphorylated in a GSK-3-dependent manner.
Alzheimer's disease (AD) and other neurodegenerative pathologies, as well as other types of diseases like diabetes, cardiovascular problems, and cancer, are caused by the dysfunction or abnormal activity of GSK-3. GSK-3 is a prime candidate for therapeutic intervention because it is also connected to innate immune defense against pathogens.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3821 | Laduviglusib (CHIR99021) trihydrochloride | 1782235-14-6 | Laduviglusib (CHIR99021; CHIR-99021) 3HCl, the trihydrochloride salt form of CHIR-99021 (also called CT99021 or CHIR-911), is a potent and orally bioavailable GSK-3α/β (glycogen synthase kinase 3α/β) inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; CHIR-99021 was proved to promote self-renewal and maintain pluripotency of both B6 and BALB/c ES cells via stabilizing the downstream effectors like c-Myc and β -catenin. |
|
V0223 | LY2090314 | 603288-22-8 | LY2090314 (LY-2090314) is a novel and potent GSK-3 (glycogen synthase kinase-3) inhibitor for GSK-3α/β with potential antitumor activity. |
|
V69850 | PF-04802367 (PF-367) | 1962178-27-3 | PF-04802367 (PF-367) is a selective GSK-3 inhibitor (antagonist) with IC50 of 2.1 nM for GSK-3β enzyme. |
|
V69846 | PfGSK3/PfPK6-IN-2 | 2797225-47-7 | PfGSK3/PfPK6-IN-2 is a potent dual (bifunctional) inhibitor of PfGSK3/PfPK6 (Plasmodium falciparum GSK3/PK6) (IC50= 172 nM and 11 nM, respectively). |
|
V69840 | Phospho-Glycogen Synthase Peptide-2(substrate) | 851366-97-7 | Phospho-Glycogen Synthase Peptide-2 (substrate) is a bioactive peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein serine kinases. |
|
V76635 | Phospho-Glycogen Synthase Peptide-2(substrate) TFA | Phospho-Glycogen Synthase Peptide-2 (substrate) is a bioactive peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein serine kinases. | |
|
V69848 | PIMPC | 2250244-44-9 | PIMPC is a compound with antioxidant and metal chelating properties. |
|
V81232 | PROTAC GSK-3β Degrader-1 | PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targeting GSK-3β with IC50 of 833 nM. | |
|
V69854 | SAR502250 | 503860-57-9 | SAR502250 is a specific, ATP-competitive, orally bioactive and BBB (blood-brain barrier) permeable (penetrable) GSK3 inhibitor (antagonist) with IC50 of 12 nM for human GSK-3β. |
|
V0212 | SB216763 | 280744-09-4 | SB216763 is a novel, potent and selective GSK-3 (glycogen synthase kinase-3) inhibitor with anti-inflammatory activiity and neuro-protective effects as it canpromote DNA repair in ischemic retinal neurons. |
|
V0216 | SB415286 | 264218-23-7 | SB415286 is a novel, potent,selective, cell permeable and ATP-competitive GSK3α (glycogen synthase kinase-3alpha) inhibitor with potential anti-inflammatory activity. |
|
V0222 | TDZD-8 (NP-01139) | 327036-89-5 | TDZD-8(NP01139; GSK3 Inhibitor I) is a novel, potent and non-ATP competitive GSK-3β (glycogen synthase kinase-3beta) inhibitor with the potential for treating neurodegenerative diseases such as PD (parkinson disease). |
|
V0215 | Tideglusib (NP-031112, NP-12) | 865854-05-3 | Tideglusib (formerly known as NP031112, NP12) is a novel, potent, irreversible, non-ATP-competitive and chemical inhibitor of GSK-3β (glycogen synthase kinase-3β) with potentialneuroprotective effects and may be used as an anti-AD (Alzheimer disease) agent. |
|
V0214 | TWS119 | 601514-19-6 | TWS119, apyrrolopyrimidine compound, is a novel, potent and selective/specific GSK-3β (Glycogen synthase kinase-3β) inhibitor with potentialusefulness for in vivo stem cell biology and therapy. |
|
V60040 | WAY-624687 | 753473-65-3 | WAY-624687 is a GSK-3 inhibitor |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
